



The following formulary decisions and updates apply to **Optum Rx® standard EHB formularies**.

The Optum Rx Business Committee meets monthly to evaluate tier placements and new prescription products approved by the Food and Drug Administration (FDA). This committee makes decisions based on information and recommendations from the Optum Rx Pharmacy & Therapeutics Committee, comprised of independent physician providers and pharmacists.

The following are the strategic clinical decisions made in the past month. Your actual plan's copays and/or coinsurance may differ from those indicated depending on the selected plan design, which determines coverage and pharmacy provider(s).

The tier chart below does not necessarily correlate to Centers for Medicare and Medicaid Services (CMS) submission tiers.

HIX BASE (RxBuilder) Tiers	HIX ENHANCED (RxBuilder) Tiers
Generic = 1	Low-Cost Generic = LCG
Preferred Brand = 2	Generic = 1
Non-Preferred Brand = 3	Preferred Brand = 2
Specialty = 4	Non-Preferred Brand = 3
Both versions include preventive (PV) drugs which may have \$0 when health care reform requirements are met.	Specialty Generic & Specialty Preferred Brands = 4
Both versions may contain Oral Chemo (CM) tier if elected.	Specialty Non-Preferred Brands = 5

**Key**    **SP:** Specialty Pharmacy    **PA:** Prior Authorization    **ST:** Step Therapy    **QL:** Quantity Limits

## Down-tiers

Medications may move to a lower tier or be added to the formulary throughout the year, helping members take immediate advantage of cost savings.

Therapeutic use	Medication name	EHB Base	EHB Enhanced	Programs				Effective date
				SP	PA	ST	QL	
Oncology	Mekinist solution (trametinib) .05MG/ML	EXC > Tier 4	EXC > Tier 4	---	X	---	---	10/1/23
	Tafinlar (dabrafenib) Tablets 10mg	EXC > Tier 4	EXC > Tier 4	---	X	---	---	10/1/23

EXC: Excluded

## Up-tiers

Medications may move to a higher tier on Jan. 1.

Please note there are no up-tiers at this time.

## New brand launches and new strengths

New brand name medications and new strengths launch throughout the year. Final coverage status for new medications is determined after thorough review by the Optum Rx Pharmacy & Therapeutics Committee. New brand launches may include Authorized Brand Alternatives.\*

Therapeutic use	Medication name	EHB Base	EHB Enhanced	Programs				Effective date
				SP	PA	ST	QL	
Anti-Infective Agents	Beyfortus (niservimab-alip) IM inj	Tier 2	Tier 2	---	---	---	---	9/28/23

\*Authorized Brand Alternatives (ABA), also referred to as Authorized Generics, are approved brand name medications marketed by either the brand company or another company. Although it does not have the brand name on its label, it is the exact same drug product as the brand product.

## New generic launches

New generic medication launches occur throughout the year.

Therapeutic use	Generic medication name	Brand medication name	EHB Base	EHB Enhanced	Programs				Effective date
					SP	PA	ST	QL	
ADHD Agents	lisdexamfetamine capsule and chewable tablet	Vyvanse	Tier 1	Tier 1	---	---	---	---	8/28/23
Respiratory Agents	tiotropium bromide capsule	Spiriva	Tier 2	Tier 2	---	---	---	X	9/6/23

## PA Prior Authorization

Prior Authorization requires physicians to provide additional clinical information to verify member benefit coverage.

Therapeutic use	Medication name	Add/Remove	Effective date
Blood Modifiers	Mozobil (plerixafor)	Remove	11/1/23
	plerixafor	Remove	11/1/23
Oncology	Mekinist solution (trametinib) .05MG/ML	Add	10/1/23
	Tafinlar (dabrafenib) Tablets 10mg	Add	10/1/23

## ST Step Therapy

Step Therapy directs members to try a lower-cost alternative (Step 1) before a higher-cost medication (Step 2) may be eligible for coverage.

Therapeutic use	Medication name	Add/Remove	Effective date
Antidiabetic Agents	Farxiga (dapagliflozin) tablet	Remove	9/1/23
	Glyxambi (empagliflozin-linagliptin) tablet	Remove	9/1/23

Therapeutic use	Medication name	Add/Remove	Effective date
Antidiabetic Agents	Jardiance (empagliflozin) tablet	Remove	9/1/23
	Synjardy & Synjardy XR (empagliflozin-metformin) tablet	Remove	9/1/23
	Xigduo XR (dapagliflozin-metformin) tablet	Remove	9/1/23
	ciprofloxacin 0.2% otic solution	Remove	9/1/23

## QL Quantity limits

Quantity limits establish the maximum quantity of a drug that is covered within a specified timeframe.

Therapeutic use	Medication name	Add/Remove	Effective date
Anticoagulants	enoxaparin SC injection	Remove	10/1/23
	fondaparinux SC injection	Remove	10/1/23

## AR Age restrictions (this applies to a limited number of clinical programs)

*Please note there are no additions or removals of this restriction at this time.*



If you would like additional information that is not listed,  
please contact your Optum Rx representative.

At Optum, we help create a healthier world, one insight, one connection, one person at a time.

All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions.  
All other trademarks are the property of their respective owners.

© 2023 Optum, Inc. All rights reserved. OPT6773729\_EHBSeptember2023

**Optum Rx**<sup>®</sup>